Weather , , 0°C

Major Depressive Disorder market dynamics are anticipated to change in the coming years due to the rising awareness of the disease and better approaches to therapy development across the world

 Breaking News
  • No posts were found

Major Depressive Disorder market dynamics are anticipated to change in the coming years due to the rising awareness of the disease and better approaches to therapy development across the world

September 15
22:20 2021
Major Depressive Disorder market dynamics are anticipated to change in the coming years due to the rising awareness of the disease and better approaches to therapy development across the world
Major Depressive Disorder Market
The expected launch of emerging therapies is expected to significantly impact the Major Depressive Disorder market size during the forecast period (2021–2030).

DelveInsight’s Major Depressive Disorder market report provides a comprehensive understanding of the Major Depressive Disorder, historical and forecasted epidemiology, and the market trends in the 7MM.

Key Takeaways from the Major Depressive Disorder Market Report

  • As per DelveInsight estimates, the Major Depressive Disorder 12-month prevalence was over 43 million in the 7MM in 2020.

  • Among the EU5 countries, France had the highest Major Depressive Disorder 12-month prevalence.

  • Pharmaceutical companies such as Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Therapeutics, Relmada Therapeutics, Praxis Precision Medicines, VistaGen Therapeutics, Intra-Cellular Therapies, and others are among others that are involved in developing therapies for Major Depressive Disorder. 

  • Key Major Depressive Disorder pipeline therapies in the market include AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, and several others.

  • AXS-05 (Axsome Therapeutics) is an investigational NMDA receptor antagonist with a multimodal activity that is being developed to treat major depressive disorder and other central nervous system disorders.

  • The USFDA has granted SAGE-217 (Sage Therapeutics) Fast Track and Breakthrough Therapy designation to treat major depressive disorder.

  • REL-1017 (Relmada Therapeutics) is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist that could become the first oral single-agent NMDAR antagonist approved for the adjunctive treatment of MDD.

Request for the Webex demo of the report @ Major Depressive Disorder Market Outlook

The Major Depressive Disorder market report also discusses current Major Depressive Disorder symptoms treatment practices/algorithms, market drivers, market barriers, and unmet medical needs.

Major Depressive Disorder: Overview

One of the most frequent psychiatric diseases is Major Depressive Disorder. The World Health Organization predicts that it will be the leading cause of disease burden in high-income countries by 2030. It is characterized by persistent sadness, loss of interest or pleasure, low energy, poor appetite and sleep, and even suicidal ideation, all of which disrupt daily activities and psychosocial functions.

Major Depressive Disorder Epidemiology Segmentation

The Major Depressive Disorder report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Major Depressive Disorder 12 Months Prevalent Cases

  • Major Depressive Disorder Gender-Specific Prevalent Cases

  • Major Depressive Disorder Severity-Specific Prevalent Cases

  • Major Depressive Disorder Relapsed/Refractory Cases

Major Depressive Disorder Treatment Landscape

The Major Depressive Disorder treatment is divided into phases: the acute phase, the continuation phase, and the maintenance phase. First-line pharmacotherapy alternatives include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), whereas, Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) are used as second-line pharmacotherapy options.

Furthermore, Brintellix (Takeda Pharmaceutical), Fetzima (Forest Laboratories), Rexulti (Otsuka Pharmaceuticals), Spravato (Janssen Research and Development), and others are some of the FDA-approved drugs for Major Depressive Disorder. 

Major Depressive Disorder Market

The Major Depressive Disorder therapeutic market size was USD 3,960.6 million in the 7MM in 2020. 

The Major Depressive Disorder market size is anticipated to grow due to pharmaceutical companies’ extensive research and development activities and upcoming therapies such as  AXS-05, Pramipexole, SAGE-217 LY03005, Seltorexant, and others during the forecast period (2021-30).

Get a detailed analysis of the market @ Major Depressive Disorder Market Size

Major Depressive Disorder Pipeline Therapies and Key Companies

  • AXS-05: Axsome Therapeutics

  • Pramipexole: Chase Therapeutics

  • SAGE-217: Sage Therapeutics

  • LY03005: Luye Pharma Group

  • Seltorexant: Minerva Therapeutics

  • PH10: VistaGen Therapeutics

  • PRAX-114: Praxis Precision Medicines

  • REL-1017: Relmada Therapeutics

  • Caplyta: Intra-Cellular Therapies

Table of Contents 

1.

Key Insights

2.

Report Introduction

3.

Major Depressive Disorder Market Overview at a Glance

4.

Executive Summary of Major Depressive Disorder

5.

Major Depressive Disorder Disease Background and Overview

6.

Major Depressive Disorder Epidemiology and Patient Population

7.

Major Depressive Disorder Treatment and Management

8.

Organizations contributing toward MDD

9.

Major Depressive Disorder Patient Journey

10.

Case Report

11.

Major Depressive Disorder Marketed Therapies

12.

Major Depressive Disorder Emerging Therapies

13.

Major Depressive Disorder Discontinued Therapies

14.

No Development Reported

15.

Major Depressive Disorder: 7 Major Market Analysis

16.

Major Depressive Disorder Market Outlook by Country

17.

Major Depressive Disorder Market Drivers

18.

Major Depressive Disorder Market Barriers

19.

SWOT Analysis

20.

Major Depressive Disorder Unmet Needs

21.

Major Depressive Disorder Market Access

22.

Appendix

23.

DelveInsight Capabilities

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Treatment-Resistant Depression Market

Get a comprehensive analysis of Treatment-Resistant Depression pipeline therapies and key companies such as Eli Lilly and Company, Johnson& Johnson, Alkermes, Axsome Therapeutics, Celon Pharma, among others.

About DelveInsight

DelveInsight is a renowned business consulting and market research firm specializing in the life sciences. It helps pharma companies improve their performance by delivering comprehensive end-to-end solutions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles

Calendar

October 2021
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031

Categories